menthol has been researched along with Acute Pain in 2 studies
Menthol: A monoterpene cyclohexanol produced from mint oils.
Acute Pain: Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.
Excerpt | Relevance | Reference |
---|---|---|
"The mean migraine duration was 18." | 3.11 | A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. ( Arkuszewski, M; Ecochard, L; Kim, BK; Li, Z; Lian, Y; Su, W; Wan, Q; Wang, H; Wang, SJ; Wen, S; Yin, F; Yu, S; Yu, T; Zhou, J, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Yu, S | 3 |
Kim, BK | 3 |
Wang, H | 3 |
Zhou, J | 3 |
Wan, Q | 3 |
Yu, T | 3 |
Lian, Y | 3 |
Arkuszewski, M | 3 |
Ecochard, L | 3 |
Wen, S | 3 |
Yin, F | 3 |
Li, Z | 3 |
Su, W | 3 |
Wang, SJ | 3 |
Liu, B | 1 |
Fan, L | 1 |
Balakrishna, S | 1 |
Sui, A | 1 |
Morris, JB | 1 |
Jordt, SE | 1 |
1 trial available for menthol and Acute Pain
Article | Year |
---|---|
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
1 other study available for menthol and Acute Pain
Article | Year |
---|---|
TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain.
Topics: Acute Pain; Analgesia; Animals; Cells, Cultured; Inflammation; Male; Menthol; Mice; Mice, Inbred C57 | 2013 |